Related references
Note: Only part of the references are listed.Carnosine decreased neuronal cell death through targeting glutamate system and astrocyte mitochondrial bioenergetics in cultured neuron/astrocyte exposed to OGD/recovery
Li Ouyang et al.
BRAIN RESEARCH BULLETIN (2016)
Minocycline as Adjunctive Treatment to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind Placebo-Controlled Trial
Ali Ghaleiha et al.
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY (2016)
N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial
K. Paydary et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2016)
Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study
Sahra Emamzadehfard et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2016)
Cognitive behavioral and pharmacological treatments of OCD in children: A systematic review and meta-analysis
Lars-Goran Ost et al.
JOURNAL OF ANXIETY DISORDERS (2016)
N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study
Jerome Sarris et al.
CNS DRUGS (2015)
Riluzole Augmentation in Treatment-Refractory Obsessive-Compulsive Disorder: A Pilot Randomized Placebo-Controlled Trial
Christopher Pittenger et al.
JOURNAL OF CLINICAL PSYCHIATRY (2015)
Protective effect of carnosine on febrile seizures in immature mice
Yun-Jian Dai et al.
NEUROSCIENCE LETTERS (2015)
Celecoxib as an Adjuvant to Fluvoxamine in Moderate to Severe Obsessive-compulsive Disorder: A Double-blind, Placebo-controlled, Randomized Trial
M. Shalbafan et al.
PHARMACOPSYCHIATRY (2015)
N-Acetyl Cysteine in the Treatment of Obsessive Compulsive and Related Disorders: A Systematic Review
Georgina Oliver et al.
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE (2015)
Glutamate Modulators in the Treatment of Obsessive-Compulsive Disorder
Christopher Pittenger
PSYCHIATRIC ANNALS (2015)
Anserine and carnosine supplementation in the elderly: Effects on cognitive functioning and physical capacity
D. Szczesniak et al.
ARCHIVES OF GERONTOLOGY AND GERIATRICS (2014)
Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder
Mahnaz Heidari et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2014)
Memantine add-on in moderate to severe obsessive-compulsive disorder: Randomized double-blind placebo-controlled study
Ali Ghaleiha et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2013)
In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD)
Mohammad Haghighi et al.
PSYCHOPHARMACOLOGY (2013)
Granisetron Adjunct to Fluvoxamine for Moderate to Severe Obsessive-Compulsive Disorder A Randomized, Double-Blind, Placebo-Controlled Trial
Neda Askari et al.
CNS DRUGS (2012)
The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder
Me Wu et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2012)
A preliminary, randomized, double-blind, placebo-controlled trial of L-carnosine to improve cognition in schizophrenia
K. N. Roy Chengappa et al.
SCHIZOPHRENIA RESEARCH (2012)
A 2012 Evidence-Based Algorithm for the Pharmacotherapy for Obsessive-Compulsive Disorder
Dan J. Stein et al.
CURRENT PSYCHIATRY REPORTS (2012)
Carnosine protects against permanent cerebral ischemia in histidine decarboxylase knockout mice by reducing glutamate excitotoxicity
Yao Shen et al.
FREE RADICAL BIOLOGY AND MEDICINE (2010)
A Single-Blinded Case-Control Study of Memantine in Severe Obsessive-Compulsive Disorder
S. Evelyn Stewart et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2010)
Memantine Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder An Open-Label Trial
Elias Aboujaoude et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2009)
Anti-Brain Autoantibodies and Altered Excitatory Neurotransmitters in Obsessive-Compulsive Disorder
Sagnik Bhattacharyya et al.
NEUROPSYCHOPHARMACOLOGY (2009)
Anatomy and physiology of the basal ganglia: Implications for DBS in psychiatry
Brian Harris Kopell et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2008)
Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study
Shahin Akhondzadeh et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2008)
N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: A pilot study
Jon E. Grant et al.
BIOLOGICAL PSYCHIATRY (2007)
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder
M. H. Bloch et al.
MOLECULAR PSYCHIATRY (2006)
Treatment-refractory obsessive-compulsive disorder: Methodological issues, operational definitions and therapeutic lines
S Pallanti et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2006)
Response versus remission in obsessive-compulsive disorder
HB Simpson et al.
JOURNAL OF CLINICAL PSYCHIATRY (2006)
N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder
DL Lafleur et al.
PSYCHOPHARMACOLOGY (2006)
Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial
V Coric et al.
BIOLOGICAL PSYCHIATRY (2005)
Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders
MG Chez et al.
JOURNAL OF CHILD NEUROLOGY (2002)
Treatment non-response in OCD: methodological issues and operational definitions
S Pallanti et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2002)
Cerebral metabolism in major depression and obsessive-compulsive disorder occurring separately and concurrently
S Saxena et al.
BIOLOGICAL PSYCHIATRY (2001)
Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder
MJ McGrath et al.
BRAIN RESEARCH (2000)
Share Paper
